

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 9649
LEE <i>et al.</i>	Art Unit: 1646
Appl. No.: 10/567,381	Examiner: Wegert, Sandra L.
§ 371(c) Date: February 26, 2008	Atty. Docket: 2681.0430002/EJH/JBF
For: NOGO Receptor Antagonists	

Reply to Restriction Requirement and Election of Species

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Restriction Requirement dated June 10, 2010, requesting an election of one group to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the claims in Group I, represented by claims 1, 2, 4, 5, and 7. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made **with traverse.**

Applicants respectfully assert that this Restriction Requirement based on lack of unity of invention is unfounded. According to 37 C.F.R. § 1.475(a), "a national stage application shall relate to one invention only *or to a group of inventions so linked as to form a single general inventive concept.*" *Id.* (emphasis added). The Manual of Patent Examining Procedure (M.P.E.P.) provides the following guidance regarding "a single general inventive concept:

A group of inventions is considered linked to form a single general inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature. The expression special technical features is defined as